Purchase this article with an account.
M. Zas, J. P. Francos, P. Koll; Intravitreal Bevacizumab (Avastin) as Monotherapy for Macular Edema Secondary to Branch and Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3570.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate anatomic, efficacy and visual acuity response after intravitreal Bevacizumab injection in patients with macular edema secondary to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).
Twenty-four patients (24 patients, 24 eyes, 8 CRVO, 16 BRVO) were retrospectively assessed. Examination included best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in the optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow up visits in all the cases. Two intravitreal injections of bevacizumab 1.25 mg (0.05 ml) were administrated at 4-week intervals. Retreatments were based on BCVA and CRT findings. Follow-up examinations were performed at 24 and 48 hours post injection and then at approximately monthly intervals (± 1 week) for up to 12 months.
At baseline, mean BCVA was 20/381 (median 20/400) and improved to mean 20/135 (median 20/60) after one month (P = .001). At 4 months mean BCVA was 20/178 (median 20/80) (P = .001). Mean CRT was 583 µm (range 356-810) at baseline and decreased to 292 µm (median 221µm) after 48 hours (P = .001).At 12 months, BCVA was 20/125 (median at 20/50) (P = .001) and CRT was 310 µm (median 270 µm) (P = .001). FA showed no evidence of increased avascular zones. Complications (endophtalmitis, increased intraocular pressure, retinal detachment) were not detected.
In patients with macular edema secondary to branch and central retinal vein occlusion, intravitreal bevacizumab injection appears to be an effective and safe current therapeutic option.
This PDF is available to Subscribers Only